Valuation: Genelux Corporation

Market Cap 118M 102M 95.42M 87.53M 165M 11.24B 167M 1.12B 439M 5.63B 444M 434M 18.63B P/E 2026 *
-3.24x
P/E 2027 * -3.56x
Enterprise Value 118M 102M 95.42M 87.53M 165M 11.24B 167M 1.12B 439M 5.63B 444M 434M 18.63B EV / Sales 2026 *
-
EV / Sales 2027 * 9.7x
Free-Float
86.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.48%
1 week-9.52%
Current month-9.52%
1 month-10.44%
3 months-6.01%
6 months+11.30%
Current year-38.99%
1 week 2.5
Extreme 2.5
3.08
1 month 2.5
Extreme 2.5
3.08
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 52 02/01/2026
Director TitleAgeSince
Director/Board Member 68 01/09/2002
Chairman 73 01/01/2014
Chairman 67 01/04/2023
Date Insider Type Main position Quantity % Market Cap.
8/4/26 A Sell

Chief Technology Officer

-653 0.0015%
8/4/26 A Sell

Chief Technology Officer

-653 0.0015%
8/4/26 A Sell

Chief Executive Officer

-3,023 0.0067%
Change 5-day change 1-year change 3-year change Capi.($)
-1.48%-9.52%-20.36%-88.82% 118M
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.31%+9.56%+45.58%+177.41% 26.37B
Weighted average by Cap. +4.35%+13.09%+49.45%+168.37%

Financials

2026 *2027 *
Net sales - 12.18M 10.54M 9.84M 9.03M 16.98M 1.16B 17.25M 115M 45.31M 581M 45.75M 44.74M 1.92B
Net income -37.1M -32.09M -29.97M -27.49M -51.71M -3.53B -52.53M -352M -138M -1.77B -139M -136M -5.85B -37.87M -32.75M -30.59M -28.06M -52.78M -3.6B -53.62M -359M -141M -1.81B -142M -139M -5.97B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
07/08/26 $2.660 -1.48% 246,818
06/08/26 $2.700 +7.57% 209,650
05/08/26 $2.510 -10.99% 950,188
04/08/26 $2.820 -5.37% 787,371
03/08/26 $2.980 +1.36% 219,562
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.660USD
Average target price
17.50USD
Spread / Average Target
+557.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock